Ryan D. Christensen, M.D.
Work History
2010 - Present:
- Retina Associates, LLC
8600 Quivira Road
Lenexa, KS 66215 - Retina Associates, LLC
6201 College Boulevard
Suite 200
Overland Park, KS 66211 - Retina Associates. LLC
4100 North Mulberry Drive
Suite 100
Kansas City, MO 64116 - Retina Associates, LLC
6001 SW 6th Avenue
Suite 300
Topeka, KS 66615 - Retina Associates, LLC
3400 W 10th Street
Sedalia, MO 65301 - Retina Associates, LLC
100 NE Missouri Road
Suite 203
Lee's Summit, MO 64086
2008 - 2009
- University of Kansas School of Medicine - Kansas City Clinical Faculty, Vitreoretinal Medicine and Surgery
1990 - 2004
- USD 385 - Andover Kansas Substitute Teacher, 2004
- USD 266 - Maize, Kansas Substitute Teacher, 2004
- Boy Scouts of America, Philmont Scout Ranch, Camp Medic, 2003
- Kansas State University, Department of Anatomy and Physiology, Student Teaching Assistant - Cadaver Lab, 2000
- Kansas State University, Department of Anatomy and Physiology, Student Teaching Assistant - Human Anatomy, 1999
- Fry Eye Associates, Garden City Kansas, Ophthalmic Technician, 1998 - 1999
- Christensen Animal Clinic, Garden City, Kansas, Veterinary Assistant, 1990 - 1995
Education
-Vitreoretinal Fellowship: Retina Associates, LLC. – Lenexa, KS 2008-2010
- Ophthalmology Residency: University of Kansas School of Medicine – Kansas City, KS 2005-2008
- Internal Medicine Internship: University of Kansas School of Medicine – Wichita, KS 2004 -2005
- Clinical Clerkship – Medical School: University of Kansas School of Medicine – Wichita, KS 2002-2004
- Basic Science Clerkship – Medical School: University of Kansas School of Medicine – Kansas City, KS 2000-2002
- Bachelor of Science – Biology: Kansas State University – Manhattan, KS 1995-2000
- Garden City Community College – Garden City, KS 1996-1997
- Garden City High School – Garden City, KS 1991-1995
Professional Associations
- American Academy of Ophthalmology
- American Board of Ophthalmology
- Kansas City Society of Ophthalmology and Otolaryngology
- Kansas City Society of Ophthalmology and Otolaryngology Journal Club
- Kansas Medical Society
- Kansas Society of Eye Physicians and Surgeons
- Missouri Society of Eye Physicians and Surgeons
- Missouri State Medical Association
Scholarly Presentations
- Fluorescein Angiography #101, 2008/09 - KU Eye - Monthly lecture series
- Posterior Parasitic Uveitis, 11/2007 - KU Eye Grand Rounds
- Parasitic Uveitis: Worm in the Eye!! 02/2007 - High Plain’s Eye Society Winter Symposium
- Adherence to Preferred Practice Patterns in ARMD, 06/2007 - KU Eye Grand Rounds
- AAO Mid-Year Forum 2007, 06/2007 - KU Eye Grand Rounds
- Orbital Masses – A Differential Diagnosis, 05/2007 - Children’s Mercy Hospital Grand Rounds
- Eyelid Tumors - Clinical Diagnosis and Histology 101, 09/2006 - KU Eye Grand Rounds
-Herpetic Corneal Disorders, 07/2006 - KU Eye New Resident Orientation - Common Corneal Disorders, 07/2006 - KU Eye New Resident Orientation
- Cogan's Syndrome - Oculovestibuloauditory Syndrome, 06/2006 -KU Eye Resident Research Day
- LASIK and Excimer Laser Evolution, 03/2006 - KU Eye Grand Rounds
- Aceruloplasminemia – Fundus and Fluorescein Angiography, 04/2006 - KU Medical Center Internal Medicine Grand Rounds
- The Red Eye - A Differential Diagnosis, 07/2005 - KU Medical Center Pediatrics Morning Report
Clinical Research
- Alcon: RTH258-C001, Sub-Investigator, RTH258 versus Aflibercept for Patients With NVAMD, 05/2015 - 05/2018.
- Allergan: 208397-001, Sub-Investigator, AGN-208397 for the Treatment of Macular Edema Secondary to Retinal Vein Occlusion, 11/2010 - 2013.
- Eyetech: EOP1024, Sub-Investigator, Evaluating the Effects of Intravitreal Injections of Pegaptanib for NVAMD on the Corneal Endothelium, 2010 - 04/2012.
- Genentech: FVF4168g, Sub-Investigator, Intravitreal Injection of Ranibizumab for Diabetic Macular Edema, 2008 - 12/2012
- Genentech: FVF4166g, Sub-Investigator, Intravitreal Injection of Ranibizumab for Central Retinal Vein Occlusion, 2008-2010.
- Genentech: FVF4165g, Sub-Investigator, Intravitreal Injection of Ranibizumab for Branch Retinal Vein Occlusion 2008-2010.
- Genentech: FVF3426g, Sub-Investigator, Intravitreal Injection of Ranibizumab for BRVO & CRVO Patients who Completed
- Genentech Sponsored Ranibizumab Study 2009-2010.
- Genentech: FVF4579g, Sub-Investigator, Intravitreal Injection of Ranibizumab for Subfoveal Neovascular AMD 2009 - 09/2012.
- Genentech: FVF4967g, Sub-Investigator, Intravitreal Injection of Ranibizumab for BRVO, CRVO, & HRVO , 03/2011 - 01/2013.
- Genentech: GX29176, Sub-Investigator, Inravitreal Injection or Lampalizumab for GA Secondary to NNVAMD, 11/2014 - 04/2018.
- Genentech: GX30191, Sub-Investigator, Intravitreal Lampalizumab for Patients With GA Who Completed the Parent Study GX29176, 11/2016 - 04/2018.
- Genentech: GR40548, Sub-Investigator, Port Delivery System versus Intravitreal Ranibizumab for Patients with NVAMD, 11/2018 - present.
- Genentech: GR40349, Sub-Investigator, Intravitreal Faricimab for Patients With DME, 11/2018 - present.
- Lux BioScience: LX211-11, Sub-Investigator, Study to Assess the Efficacy and Safety of Voclosporin as Therapy in Subjects With Active, Noninfectious, Intermediate, Posterior or Pan-Uveitis, 01/2011 - 01/2012.
- MyLan: MYL-1701P-3001, Sub-Investigator, MYL-1701P versus Aflibercept for Patients With DME, 08/2018 - present.
- Novartis: CRTH258B2301, Sub-Investigator, Brolucizumab versus Aflibercept for Patients With Visual Impairment Due to DME, 09/2018 - present.
- Novartis: CRTH258AUS04, Sub-Investigator, Brolucizumab versus Aflibercept for Patients With NVAMD With Persistent Sub-Retinal Fluid, 12/2018 - present.
- Ophthotech: OPH3000, Sub-Investigator, Intravitreal Injection of Volocixumab in Combination with Ranibizumab for NVAMD, 2008 - 2009.
- Ophthotech: OPH1001, Sub-Investigator, Intravitreal Injection of E10030 in Combination with Ranibizumab for NVAMD 2010 - 11/2011.
- Ophthotech: OPH1003, Sub-Investigator, Intravitreal Injection of Fovista in Combination With Ranibizumab versus Ranibizumab Monotherapy for Patients With NVAMD, 10/2013 - 02/2017.
- Opthea: OPT-302-1002, Sub-Investigator, Intravitreal OPT-302 in Combination With Ranibizumab versus Ranibizumab Alone for NVAMD, 12/2017 - present.
- PanOptica: PAN01-010, Sub-Investigator, Topical Ocular PAN-90806 for Patients With NVAMD, 02/2014 - 02/2016.
- NEI: SCORE2, Sub-Investigator, Bevacizumab versus Aflibercept for Macular Edema Secondary to Central Retinal Vein Occlusion, 10/2014 - 10-2016.
- Regeneron: R2176-3-AMD-1417, Sub-Investigator, REGN2176-3 for Patients With NVAMD, 05/2015 - 04/2017.
- Regeneron: R910-3-DME-1518, Sub-Investigator, REGN910-3 for Patients With DME, 04/2016 - 10/2017.